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INTRODUCTION:  We  describe  a case  of  a large  type  III  neuroendocrine  tumor  of  the  stomach.  Management
and  current  literature  are  reviewed.
PRESENTATION  OF  CASE:  A  37  year  old  female  presented  with  upper  gastrointestinal  bleed  and  epigas-
tric  pain.  Further  workup  demonstrated  a large  ulcerated  gastric  mass near  the  GE junction.  Computer
tomography  scan and  endoscopic  ultrasound  showed  a  10 cm mass  with  no  evidence  of distant  disease.
Fine needle  aspiration  pathology  was  consistent  with  a well  differentiated  neuroendocrine  tumor  (Ki67
index  <2%),  with elevated  levels  of chromogranin  A  and  serotonin  levels  but normal  gastrin.  The  patient
underwent  an  uneventful  total  gastrectomy.  Final  pathology  analysis  reported  a  higher KI67 index  (7.54%)
and a ﬁnal  pathology  of  grade  2 type  III,  T3 N3,  neuroendocrine  tumor  of  the  stomach.  The  chromogranin
levels  normalized  and  no  recurrent  disease  has  been  detected  in one  year  follow  up.
DISCUSSION:  Gastric  neuroendocrine  tumors  are  extremely  rare,  accounting  for 4%  of all  neuroendocrine
tumors  of  the  body  and  1%  of  all  neoplasms  of  the  stomach.  Based  on  histomorphologic  characteristics
and  pathogenesis,  gastric neuroendocrine  tumors  are  classiﬁed  into  four types  with  differing  prognosis
and  behavior.  Current  literature  describes  type  3 gastric  neuroendocrine  tumors  as  larger  than  2  cm.
However,  there  is  no  precedent  in  the  literature  for a  tumor  of  this  size.
CONCLUSION:  The  incidence  of gastric  neuroendocrine  tumors  has been  increasing  during  the  last  decade,
underscoring  the  need  to  improve  our understanding  of their biology  and  behavior.  When  identiﬁed
histologically,  patient  outcomes  depend  on appropriate  determination  of tumor  biology  and subsequent
choice  of  treatment.
©  2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
he CCaccess  article  under  t
. Introduction
Gastroenteropancreatic neuroendocrine tumors (NETs) are rare
esions which originate in the enterocromafﬁn cells located in the
astrointestinal (GI) tract. Although they are considered indolent
umors, their clinical behavior is unpredictable and can range from
enign to malignant. NETs are subdivided into foregut (gastric, duo-
enal and pancreatic) midgut (jejunal, ileal, cecal) and hindgut
distal colic and rectal) [1], with the most common site of origin
eing the ileum, followed by the rectum and the appendix [2,3].
e describe a case of a large type III neuroendocrine tumor of the
tomach. Management and current literature are reviewed.
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2. Presentation of case
A 37 year old female presented with sudden onset epigastric
abdominal pain, and associated several episodes of hematemesis
and melena over the 3 days prior to presentation. She describes
intermittent epigastric discomfort over the past 3 years which
improved with proton pump inhibitors. On physical exam, the
abdomen was soft, non-tender, and non-distended. Rectal exam
was positive for occult blood with no other abnormal ﬁndings.
Normocytic anemia was the only abnormal routine test with a
hemoglobin value of 10. A CT scan of the abdomen and pelvis was
performed, displaying a 7 × 7 × 10 cm mass in the left upper quad-
rant, the origin of which could be either gastric or pancreatic (Fig. 1),
with no evidence of metastatic disease.
An esophagogastroduodenoscopy (EGD) was performed show-
ing a mass with a large bleeding ulcer adjacent to the
gastroesophageal junction (GEJ)(Fig. 2). Endoscopic ultrasound
(EUS) revealed a 7 cm mass in the gastric wall arising from the
mucosal layer, with no pancreatic involvement. Fine needle aspi-
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Computed Tomography of the abdomen and pelvis (axial and coronal) show-
ing  a large gastric mass.
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n
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perineural invasion (T3). Margins were free of a tumor and 7/17
F
t
a
pFig. 2. Large gastric mass with bleeding ulcer on gastroscopy.ation (FNA) was consistent with a grade I well-differentiated
euroendocrine tumor (NET) (Ki67 index < 2%). Pre-operative
ork up revealed elevated serotonin levels (460 ng/ml nor-
ig. 4. (A) Insular growth pattern: Nests of monomorphous, small round neuroendocrin
umor  (H&E, ×200 magniﬁcation). (B) Trabecular growth pattern: Tumor cells penetrate su
re  absent. (H&E, ×200 magniﬁcation). (C) Small polygonal cells with round to oval nucl
resent. (H&E, ×600 magniﬁcation). (D) Ki-67 proliferative index is 7.54%, consistent withFig. 3. Gastric mass near the gastroesophageal junction. Penrose drain around the
esophagus.
mal: 56–244 ng/ml) and chromogranin A (236 ng/ml normal:
1.9–15 ng/ml) with normal gastrin levels (33 pg—normal < 100 pg)
The patient remained stable without any further bleeding and
was discharged home, and later returned for an elective gastrec-
tomy. At the time of operation, a large gastric mass was  found 3 cm
from the GEJ (Fig. 3). A total radical gastrectomy, including perigas-
tric, left gastric and celiac lymph node dissection, was performed.
Three centimeters of distal esophagus were also included. A Roux-
en-Y reconstruction was performed and a feeding jejunostomy was
placed. Negative margins were conﬁrmed by frozen section. The
patient had an uneventful postoperative course and was  discharged
home on postoperative day 6.
Final pathology analysis showed a 10 cm well-differentiated
grade 2 type III gastric neuroendocrine tumor with subserosal andlymph nodes were positive for malignancy (N3). The tumor was
solitary, with no endocrine cell hyperplasia or atrophic gastritis,
consistent with a type III tumor (Fig. 4). Mitotic rate was  1 per
e cells without atypia or necrosis, consistent with type III gastric neuroendocrine
bserosa and grow in long cords one cell thick. Cytologic atypia, mitoses and necrosis
ei, inconspicuous nucleoli and ﬁnely dispersed chromatin. Rare mitotic ﬁgures are
 grade 2 tumor (Ki-67, ×100 magniﬁcation).
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Table  1
GNET characteristics, classiﬁcation, and prognosis [4,10,25].
Type I Type II Type III Type IV
Proportion 70–80% 5–6% 14–25% Rare
Features Multiple, 1–2 cm Multiple, 1–2 cm Single, >2 cm Single, >2 cm
Ki-67  <2% <2% >2% >30%
a or 1
.5–5%
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iWHO  classiﬁcation 1a or 1b 1
5  Year Mortality 0.5–5% 0
0 high power ﬁelds and Immunohistochemistry showed a Ki67
ndex of 7.54% assigning a grade 2 neuroendocrine tumor (G2 NET)
ccording to the world health organization (WHO) classiﬁcation
Fig. 4D). This represented a discrepancy with the prior FNA result
hich gave a Ki67 index of <2%. Chromogranin A level normalized
ne month after excision (from 240 to 4 ng/ml). CT scan of the chest
nd abdomen performed at 3, 6 and 12 months post-operatively
ave been negative for recurrence.
. Discussion
NETs can be stratiﬁed using several classiﬁcation systems,
ith the two most prevalent being the WHO  and American Joint
ommittee on Cancer. The 2010 WHO  classiﬁcation is based on
umber of mitosis and the Ki67 index giving four categories: G1
ET, G2 NET, neuroendocrine carcinoma (NEC) and mixed ade-
oneuroendocrine carcinoma (MANEC) [4]. The 2009 American
oint Committee on Cancer/Union for International Cancer Control
AJCC/UICC) classiﬁcation system uses tumor invasion, number of
ymph nodes affected and metastases (TNM) [4]. However, these
ystems are not universally accepted, making it difﬁcult to compare
ata from different centers [5].
Gastric NETs (GNETs) account for 4% of all neuroendocrine
umors of the body [6], represent between 8.7–23% of all GI tumors
f this type [3,7], and only 1% of all neoplasms of the stomach
7]. Due to an increase in routine endoscopy, their incidence has
ncreased substantially [8], and currently stands at 1–2 cases per
00,000 population per year with a female predominance and a
ean age of diagnosis of 64 years [3,9] (Table 1).
Based on histomorphologic characteristics and pathogenesis,
NETs are classiﬁed into four types that differ in prognosis and bio-
ogical behavior [10]. Type I (70–80%) is related to chronic atrophic
astritis, usually located at the gastric fundus or body with good
rognosis after resection [11]. Type II (5–6%) is often associated
ith Zollinger Ellison syndrome and MEN1. Similarly to type I,
ypes II GNETs are benign with a low risk of malignancy [12]. Type
II (14–25%) GNETs are usually sporadic tumors that quite often
nﬁltrate the muscularis propia and serosa conferring a malignant
otential. They are also associated with vascular and lymph node
nvasion and liver metastasis [13]. Type IV GNETs are very rare,
sually single, poorly differentiated and malignant, and associated
ith metastatic spread at the time of presentation [14]. Types I to
II GNETs originate from enterochromafﬁn cells, while type IV orig-
nates from other endocrine cells that secrete gastrin, serotonin or
drenocorticotrophic hormone. Types I and II are associated with
ypergastrinemia while type III and IV are gastrin independent
umors.
Type I GNETs frequently present with multiple small tumors.
a Rosa et al., [15] reported an incidence of 77% of tumors less
han 1 cm and 97% less than 1.5 cm in size. Type II GNETs are also
ultiple and less than 2 cm [9]. Type III GNETs are sporadic, iso-
ated, and larger (>2 cm), with a mean of 5 cm in size, located at
he body/fundus surrounded by normal (nonathrophic) mucosa [9].
here are currently no reports in the literature of a type III GNET
ith large dimensions as the one presented. Type IV GNETs are typ-
cally larger in size: Bordi et al. [16] presented a case of a type IVb 1b 2
 25–87% 100%
GNET measuring 16 cm,  representing one of the largest tumor sizes
ever reported.
Initial evaluation of patients with a suspected GNET should
include a serum chromogranin A level. It is elevated in approxi-
mately 80% of patients with neuroendocrine tumors regardless of
the site [17]. Elevations in Chromogranin A is frequently elevated in
Type I to III but normal in type IV, likely related to the poorly differ-
entiated nature of this tumor [10]. When the value is less than twice
the upper normal range of baseline, Chromogranin A is a predictive
factor for overall survival [18]. Measurement of gastrin levels is also
recommended due to the association of types I and II and hyper-
gastrinemia. Upper endoscopy represents an essential diagnostic
tool as the majorities of GNETs are found on endoscopic exam-
inations due to dyspeptic symptoms or anemia, and types I and
II commonly present as polypoid lesions amenable to endoscopic
resection. Biopsies of the lesions should be taken as well as biop-
sies from normal appearing stomach to determine the presence
of atrophic gastritis [19]. Endoscopic ultrasound (EUS) is recom-
mended in lesions greater than 2 cm to assess depth of invasion
[20]. An Octreotide scan can be a useful adjunct in the diagnosis of
gastric neuroendocrine tumors. FDG-PET scan is more sensitive in
the detection of G3 NETs when compared with G1 or G2 tumors
due to the highly metabolically active G3 NETs [21].
Endoscopic resection and surveillance is the treatment of choice
in the majority of cases of type 1 GNET. Lesions less than one cen-
timeter in size should be observed and carefully followed with
annual endoscopy. Lesions greater than one centimeter in size
are amenable to endoscopic resection (polypectomy, endoscopic
mucosal resection) only if the lesion is conﬁned to the mucosa or
submucosa [21]. Gastric resection for a type I and type II GNET is
recommended in patients with multifocal lesions (>4–6 lesions) or
when invasive or recurrent disease is present [21]. Since Type III
and IV GNETs behave similarly to gastric adenocarcinomas, with
a high incidence of invasion beyond the submucosa and distant
metastasis on presentation (50–100%), radical resection is recom-
mended [21]. Chemotherapy and radiation therapy is indicated
in advanced disease and as a palliative option on type IV GNET.
Combination chemotherapy regimens are most commonly admin-
istered since single-agent chemotherapy has low response rates.
The most common agents used are etoposide, cisplatin (CDDP),
and carboplatin along with somatostatin analogues octreotide and
pasireotide. Somatostatin analogues have shown a role in hormonal
symptom control and tumor suppression [10].
In general, type I and II GNETs have good overall prognosis
secondary to their benign biology with tumor-related mortality
ranging from 0.5 to 5% [10]. Close surveillance is recommended
for potential recurrence and malignant transformation. Type III
tumor-related 5 year mortality is between 25 and 30% for well-
differentiated and 75–87% for poorly-differentiated tumors [10].
Type IV GNETs have a mortality of 100% in 5 years and a mean sur-
vival of 6.5–14 months after diagnosis [10]. This case of GNET is
notable for the size of the tumor. In review of the recent literature,
the majority of cases discussed have an average diameter of 4 cm,  in
comparison with this case which was found to be 10 cm in greatest
dimension [22–24].
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. Conclusion
The incidence of gastric neuroendocrine tumors has been
ncreasing during the last decade, underscoring the need to
mprove our understanding of their biology and behavior. If a GNET
s identiﬁed histologically, patient outcomes depend on appro-
riate determination of tumor biology and subsequent choice
f treatment, surgical, medical, or both. As with all malignant
eoplasms, treatment of GNETs must have a multi-faceted and
eam-based approach, utilizing multiple modalities to improve
atient outcomes.
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